Research on the development of cancer drugs for children

Open Access

Issue		E3S Web Conf. Volume 308, 2021 2021 6^th International Conference on Materials Science, Energy Technology and Environmental Engineering (MSETEE 2021)


Article Number		02014
Number of page(s)		6
Section		Environmental Ecology and Biochemical Testing
DOI		https://doi.org/10.1051/e3sconf/202130802014
Published online		27 September 2021

Adamson, Peter C. “Improving the Outcome for Children with Cancer: Development of Targeted New Agents.” CA: A Cancer Journal for Clinicians, vol. 65, no. 3, 2015, pp. 212–220., doi:10.3322/caac.21273. [CrossRef] [PubMed] [Google Scholar]
Norris, Robin E., and Peter C. Adamson. “Challenges and Opportunities in Childhood Cancer Drug Development.” Nature Reviews Cancer, vol. 12, no. 11, 11 Nov. 2012, pp. 776–782., doi:10.1038/nrc3370. [CrossRef] [PubMed] [Google Scholar]
Garbayo, E., Pascual-Gil, S., Rodríguez-Nogales, C., Saludas, L., Estella-Hermoso, de Mendoza A., & Blanco-Prieto, M. J. (2020). Nanomedicine and drug delivery systems in cancer and regenerative medicine. WIREs Nanomedicine and Nanobiotechnology, 12(5). https://doi.org/10.1002/wnan.1637 [CrossRef] [Google Scholar]
Pritchard-Jones, Kathy, et al. “Sustaining Innovation and Improvement in the Treatment of Childhood Cancer: Lessons from High-Income Countries.” The Lancet Oncology, vol. 14, no. 3, 20 Feb. 2013, doi:10.1016/s1470-2045(13)70010-x. [Google Scholar]
Loucaides, Eva M, et al. “Global Public and Philanthropic Investment in Childhood Cancer Research: Systematic Analysis of Research Funding, 2008–16.” The Lancet Oncology, vol. 20, no. 12, Dec. 2019, doi:10.1016/s1470-2045(19)30662-x. [Google Scholar]
Adamson, Peter C. et al. “Drug Discovery in Paediatric Oncology: Roadblocks to Progress.” Nature Reviews Clinical Oncology, vol. 11, no. 12, 2014, pp. 732–739., doi:10.1038/nrclinonc.2014.149. [CrossRef] [PubMed] [Google Scholar]
Bucci-Rechtweg, Christina. “Enhancing the Pediatric Drug Development Framework to Deliver Better Pediatric Therapies Tomorrow.” Clinical Therapeutics, vol. 39, no. 10, 27 June 2017, pp. 1920– 1932., doi:10.1016/j.clinthera.2017.07.043. [CrossRef] [PubMed] [Google Scholar]
“Childhood Cancer Statistics: CureSearch.” CureSearch for Children’s Cancer, 25 Nov. 2020, curesearch.org/childhood-cancer-statistics. [Google Scholar]
Siegel, Rebecca L. et al. “Cancer Statistics, 2021.” CA: A Cancer Journal for Clinicians, vol. 71, no. 1, 12 Jan. 2021, pp. 7–33., doi:10.3322/caac.21654. [CrossRef] [PubMed] [Google Scholar]
American Cancer Society. Cancer Facts & Figures 20201. Atlanta: American Cancer Society, 2021. [Google Scholar]
Parsons, Susan K. et al. “Cost, Value, and Financial Hardship in Cancer Care: Implications for Pediatric Oncology.” American Society of Clinical Oncology Educational Book, no. 38, 2018, pp. 850–860., doi:10.1200/edbk_200359. [Google Scholar]
Kirchhoff, Anne. Health Insurance Coverage and Medical Financial Burden ... unclineberger.org/outcomes/files/2018/10/09182018 _Breakfast_Seminar_Kirchhoff.pdf. [Google Scholar]
“Eligibility.” Medicaid, www.medicaid.gov/medicaid/eligibility/index.html. [Google Scholar]
“Children’s Health Insurance Program (CHIP).” Medicaid, www.medicaid.gov/chip/index.html. [Google Scholar]
Rieder, Michael, and Daniel Hawcutt. “Design and Conduct of Early Phase Drug Studies in Children: Challenges and Opportunities.” British Journal of Clinical Pharmacology, vol. 82, no. 5, 2016, pp. 1308–1314., doi:10.1111/bcp.13058. [CrossRef] [PubMed] [Google Scholar]
McCune, Susan. “FDA Overview of the Pediatric Legislation.” FDA, 21 Nov. 2019, www.fda.gov/media/132890/download. [Google Scholar]
Center for Drug Evaluation and Research. “Pediatric Study Plans: Content of and Process for Submitting Initial Pediatric Study Plans and Amended Initial Pediatric Study Plans Guidance for Industry.” U.S. Food and Drug Administration, FDA, July 2020, www.fda.gov/regulatory-information/search-fda-guidance-documents/pediatric-study-plans-content-and-process-submitting-initial-pediatric-study-plans-and-amended. [Google Scholar]
“FDA-University of Maryland CERSI Pediatric Master Protocols Workshop.” U.S. Food and Drug Administration, 23 Sept. 2016, www.fda.gov/science-research/advancing-regulatory-science/pediatric-master-protocols#:~:text=Master%20protocols%20that%20r un%20continuousl y, focused%20on%20pediatric%20master%20protocols. [Google Scholar]
Khan, Tahira, et al. “Accelerating Pediatric Cancer Drug Development: Challenges and Opportunities for Pediatric Master Protocols.” Therapeutic Innovation & Regulatory Science, vol. 53, no. 2, 2018, pp. 270– 278., doi:10.1177/2168479018774533. [CrossRef] [PubMed] [Google Scholar]
Kantarjian, Hagop, and Leonard Zwelling. “Cancer Drug Prices and the Free-Market Forces.” Cancer, vol. 119, no. 22, 26 Aug. 2013, pp. 3903–3905., doi:10.1002/cncr.28330. [CrossRef] [PubMed] [Google Scholar]
De Oliveira, Claire, et al. “Costs for Childhood and Adolescent Cancer, 90 Days Prediagnosis and 1 Year Postdiagnosis: A Population-Based Study in Ontario, Canada.” Value in Health, vol. 20, no. 3, Mar. 2017, pp. 345–356., doi:10.1016/j.jval.2016.10.010. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.